The response to antihypertensive therapy is very heterogeneous and the need by the physicians to account for it has driven much interest in pharmacogenomics of antihypertensive drugs. The Human Genome Project and the initiatives in genomics that followed, generated a huge number of genetic data that furnished the tools to explore the genotype-phenotype association in candidate genes and at genome-wide level. In spite of the efforts and the great number of publications, pharmacogenomics of antihypertensive drugs is far from being used in clinical practice. In this review, we analyze the main findings available in PubMed from 2010 to 2015, in relation to the major classes of antihypertensive drugs. We also describe a new Phase II drug that targets two specific hypertension predisposing mechanisms.

Pharmacogenomics considerations in the control of hypertension / S. Lupoli, E. Salvi, M. Barcella, C. Barlassina. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 16:17(2015 Nov), pp. 1951-1964. [10.2217/pgs.15.131]

Pharmacogenomics considerations in the control of hypertension

S. Lupoli
Primo
;
E. Salvi
Secondo
;
M. Barcella
Penultimo
;
C. Barlassina
2015

Abstract

The response to antihypertensive therapy is very heterogeneous and the need by the physicians to account for it has driven much interest in pharmacogenomics of antihypertensive drugs. The Human Genome Project and the initiatives in genomics that followed, generated a huge number of genetic data that furnished the tools to explore the genotype-phenotype association in candidate genes and at genome-wide level. In spite of the efforts and the great number of publications, pharmacogenomics of antihypertensive drugs is far from being used in clinical practice. In this review, we analyze the main findings available in PubMed from 2010 to 2015, in relation to the major classes of antihypertensive drugs. We also describe a new Phase II drug that targets two specific hypertension predisposing mechanisms.
antihypertensive drug; association study; drug response; personalized medicine; pharmacogenomics; pharmacology; genetics; molecular medicine
Settore MED/14 - Nefrologia
Settore MED/03 - Genetica Medica
nov-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
pgs.15.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/362994
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact